Shiraz E-Medical Journal

Published by: Neoscriber Demo Publisher

Comparison of the Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Glasgow Prognostic Score in Diffuse Large B-Cell Lymphoma

Vlatka Periša 1 , 2 , * , Ana Knezović 3 , Lada Zibar 2 , 4 , Jasminka Sinčić-Petričević 1 , Danijela Mjeda 1 , Igor Periša 5 and Igor Aurer 6
Authors Information
1 Department of Hematology, Clinic of Internal Medicine, Osijek University Hospital, Osijek, Croatia
2 Department for Pathophysiology, Faculty of Medicine, University of Osijek, Osijek, Croatia
3 Community Health Centre Dakovo, Dakovo, Croatia
4 Department of Nephrology, Clinic of Internal Medicine, Osijek University Hospital, Osijek, Croatia
5 Community Health Centre Vinkovci, Vinkovci, Croatia
6 Department of Hematology, Clinic of Internal Medicine, University Hospital Centre Zagreb, Zagreb, Croatia
Article information
  • Shiraz E-Medical Journal: August 01, 2016, 17 (7-8); e38209
  • Published Online: August 16, 2016
  • Article Type: Research Article
  • Received: April 5, 2016
  • Revised: June 19, 2016
  • Accepted: August 2, 2016
  • DOI: 10.17795/semj38209

To Cite: Periša V, Knezović A, Zibar L, Sinčić-Petričević J, Mjeda D, et al. Comparison of the Prognostic Impact of Neutrophil/Lymphocyte Ratio, Platelet/Lymphocyte Ratio, and Glasgow Prognostic Score in Diffuse Large B-Cell Lymphoma, Shiraz E-Med J. 2016 ; 17(7-8):e38209. doi: 10.17795/semj38209.

Copyright © 2016, Shiraz University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Methods
4. Results
5. Discussion
  • 1. Sabattini E, Bacci F, Sagramoso C, Pileri SA. WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica. 2010; 102(3): 83-7[PubMed]
  • 2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006; 107(1): 265-76[DOI][PubMed]
  • 3. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993; 329(14): 987-94[DOI][PubMed]
  • 4. Sehn LH, Berry B, Chhanabhai M, Fitzgerald C, Gill K, Hoskins P, et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood. 2007; 109(5): 1857-61[DOI][PubMed]
  • 5. de Martino M, Pantuck AJ, Hofbauer S, Waldert M, Shariat SF, Belldegrun AS, et al. Prognostic impact of preoperative neutrophil-to-lymphocyte ratio in localized nonclear cell renal cell carcinoma. J Urol. 2013; 190(6): 1999-2004[DOI][PubMed]
  • 6. Walsh SR, Cook EJ, Goulder F, Justin TA, Keeling NJ. Neutrophil-lymphocyte ratio as a prognostic factor in colorectal cancer. J Surg Oncol. 2005; 91(3): 181-4[DOI][PubMed]
  • 7. Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology. 2007; 73(3-4): 215-20[DOI][PubMed]
  • 8. Wang DS, Luo HY, Qiu MZ, Wang ZQ, Zhang DS, Wang FH, et al. Comparison of the prognostic values of various inflammation based factors in patients with pancreatic cancer. Med Oncol. 2012; 29(5): 3092-100[DOI][PubMed]
  • 9. Szkandera J, Absenger G, Liegl-Atzwanger B, Pichler M, Stotz M, Samonigg H, et al. Elevated preoperative neutrophil/lymphocyte ratio is associated with poor prognosis in soft-tissue sarcoma patients. Br J Cancer. 2013; 108(8): 1677-83[DOI][PubMed]
  • 10. Porrata LF, Ristow K, Habermann T, Inwards DJ, Micallef IN, Markovic SN. Predicting survival for diffuse large B-cell lymphoma patients using baseline neutrophil/lymphocyte ratio. Am J Hematol. 2010; 85(11): 896-9[DOI][PubMed]
  • 11. Smith RA, Bosonnet L, Raraty M, Sutton R, Neoptolemos JP, Campbell F, et al. Preoperative platelet-lymphocyte ratio is an independent significant prognostic marker in resected pancreatic ductal adenocarcinoma. Am J Surg. 2009; 197(4): 466-72[DOI][PubMed]
  • 12. Asher V, Lee J, Innamaa A, Bali A. Preoperative platelet lymphocyte ratio as an independent prognostic marker in ovarian cancer. Clin Transl Oncol. 2011; 13(7): 499-503[DOI][PubMed]
  • 13. Wang DS, Ren C, Qiu MZ, Luo HY, Wang ZQ, Zhang DS, et al. Comparison of the prognostic value of various preoperative inflammation-based factors in patients with stage III gastric cancer. Tumour Biol. 2012; 33(3): 749-56[DOI][PubMed]
  • 14. Gunduz S, Mutlu H, Tural D, Yildiz O, Uysal M, Coskun HS, et al. Platelet to lymphocyte ratio as a new prognostic for patients with metastatic renal cell cancer. Asia Pac J Clin Oncol. 2015; 11(4): 288-92[DOI][PubMed]
  • 15. Sidaway P. Prostate cancer: Platelet-to-lymphocyte ratio predicts prostate cancer prognosis. Nat Rev Urol. 2015; 12(5): 238[DOI][PubMed]
  • 16. Liu H, Wu Y, Wang Z, Yao Y, Chen F, Zhang H, et al. Pretreatment platelet-to-lymphocyte ratio (PLR) as a predictor of response to first-line platinum-based chemotherapy and prognosis for patients with non-small cell lung cancer. J Thorac Dis. 2013; 5(6): 783-9[DOI][PubMed]
  • 17. Unal D, Eroglu C, Kurtul N, Oguz A, Tasdemir A. Are neutrophil/lymphocyte and platelet/lymphocyte rates in patients with non-small cell lung cancer associated with treatment response and prognosis? Asian Pac J Cancer Prev. 2013; 14(9): 5237-42[PubMed]
  • 18. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Evaluation of cumulative prognostic scores based on the systemic inflammatory response in patients with inoperable non-small-cell lung cancer. Br J Cancer. 2003; 89(6): 1028-30[DOI][PubMed]
  • 19. McMillan DC. The systemic inflammation-based Glasgow Prognostic Score: a decade of experience in patients with cancer. Cancer Treat Rev. 2013; 39(5): 534-40[DOI][PubMed]
  • 20. McMillan DC, Crozier JE, Canna K, Angerson WJ, McArdle CS. Evaluation of an inflammation-based prognostic score (GPS) in patients undergoing resection for colon and rectal cancer. Int J Colorectal Dis. 2007; 22(8): 881-6[DOI][PubMed]
  • 21. Ishizuka M, Nagata H, Takagi K, Horie T, Kubota K. Inflammation-based prognostic score is a novel predictor of postoperative outcome in patients with colorectal cancer. Ann Surg. 2007; 246(6): 1047-51[DOI][PubMed]
  • 22. Forrest LM, McMillan DC, McArdle CS, Angerson WJ, Dunlop DJ. Comparison of an inflammation-based prognostic score (GPS) with performance status (ECOG) in patients receiving platinum-based chemotherapy for inoperable non-small-cell lung cancer. Br J Cancer. 2004; 90(9): 1704-6[DOI][PubMed]
  • 23. Kobayashi T, Teruya M, Kishiki T, Endo D, Takenaka Y, Tanaka H, et al. Inflammation-based prognostic score, prior to neoadjuvant chemoradiotherapy, predicts postoperative outcome in patients with esophageal squamous cell carcinoma. Surgery. 2008; 144(5): 729-35[DOI][PubMed]
  • 24. Crumley AB, McMillan DC, McKernan M, McDonald AC, Stuart RC. Evaluation of an inflammation-based prognostic score in patients with inoperable gastro-oesophageal cancer. Br J Cancer. 2006; 94(5): 637-41[DOI][PubMed]
  • 25. Glen P, Jamieson NB, McMillan DC, Carter R, Imrie CW, McKay CJ. Evaluation of an inflammation-based prognostic score in patients with inoperable pancreatic cancer. Pancreatology. 2006; 6(5): 450-3[DOI][PubMed]
  • 26. Ishizuka M, Kubota K, Kita J, Shimoda M, Kato M, Sawada T. Impact of an inflammation-based prognostic system on patients undergoing surgery for hepatocellular carcinoma: a retrospective study of 398 Japanese patients. Am J Surg. 2012; 203(1): 101-6[DOI][PubMed]
  • 27. Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The Glasgow Prognostic Score, an inflammation based prognostic score, predicts survival in patients with hepatocellular carcinoma. BMC Cancer. 2013; 13: 52[DOI][PubMed]
  • 28. Li YJ, Jiang WQ, Huang JJ, Xia ZJ, Huang HQ, Li ZM. The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type. Am J Hematol. 2013; 88(5): 394-9[DOI][PubMed]
  • 29. Li X, Zhang Y, Zhao W, Liu Z, Shen Y, Li J, et al. The Glasgow Prognostic Score as a significant predictor of diffuse large B cell lymphoma treated with R-CHOP in China. Ann Hematol. 2015; 94(1): 57-63[DOI][PubMed]
  • 30. Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007; 25(5): 579-86[DOI][PubMed]
  • 31. Abakay O, Tanrikulu AC, Palanci Y, Abakay A. The value of inflammatory parameters in the prognosis of malignant mesothelioma. J Int Med Res. 2014; 42(2): 554-65[DOI][PubMed]
  • 32. Azab B, Shah N, Radbel J, Tan P, Bhatt V, Vonfrolio S, et al. Pretreatment neutrophil/lymphocyte ratio is superior to platelet/lymphocyte ratio as a predictor of long-term mortality in breast cancer patients. Med Oncol. 2013; 30(1): 432[DOI][PubMed]
  • 33. He W, Yin C, Guo G, Jiang C, Wang F, Qiu H, et al. Initial neutrophil lymphocyte ratio is superior to platelet lymphocyte ratio as an adverse prognostic and predictive factor in metastatic colorectal cancer. Med Oncol. 2013; 30(1): 439[DOI][PubMed]
  • 34. Zhang T, Jiang Y, Qu X, Shen H, Liu Q, Du J. Evaluation of preoperative hematologic markers as prognostic factors and establishment of novel risk stratification in resected pN0 non-small-cell lung cancer. PLoS One. 2014; 9(10): 111494[DOI][PubMed]
  • 35. Shimada H, Takiguchi N, Kainuma O, Soda H, Ikeda A, Cho A, et al. High preoperative neutrophil-lymphocyte ratio predicts poor survival in patients with gastric cancer. Gastric Cancer. 2010; 13(3): 170-6[DOI][PubMed]
  • 36. Zhou X, Du Y, Huang Z, Xu J, Qiu T, Wang J, et al. Prognostic value of PLR in various cancers: a meta-analysis. PLoS One. 2014; 9(6): 101119[DOI][PubMed]
  • 37. Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008; 454(7203): 436-44[DOI][PubMed]
  • 38. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002; 420(6917): 860-7[DOI][PubMed]
  • 39. Esper DH, Harb WA. The cancer cachexia syndrome: a review of metabolic and clinical manifestations. Nutr Clin Pract. 2005; 20(4): 369-76[PubMed]
  • 40. Moore MM, Chua W, Charles KA, Clarke SJ. Inflammation and cancer: causes and consequences. Clin Pharmacol Ther. 2010; 87(4): 504-8[DOI][PubMed]
  • 41. Cao Y, Shi YX, Chen JO, Tan YT, Cai YC, Luo HY, et al. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumour Biol. 2012; 33(4): 1039-44[DOI][PubMed]
  • 42. Mohri Y, Tanaka K, Ohi M, Yokoe T, Miki C, Kusunoki M. Prognostic significance of host- and tumor-related factors in patients with gastric cancer. World J Surg. 2010; 34(2): 285-90[DOI][PubMed]
  • 43. Feng J, Wang Z, Guo X, Chen Y, Cheng Y, Tang Y. Prognostic significance of absolute lymphocyte count at diagnosis of diffuse large B-cell lymphoma: a meta-analysis. Int J Hematol. 2012; 95(2): 143-8[DOI][PubMed]
  • 44. Oki Y, Yamamoto K, Kato H, Kuwatsuka Y, Taji H, Kagami Y, et al. Low absolute lymphocyte count is a poor prognostic marker in patients with diffuse large B-cell lymphoma and suggests patients' survival benefit from rituximab. Eur J Haematol. 2008; 81(6): 448-53[DOI][PubMed]
  • 45. Kim DH, Baek JH, Chae YS, Kim YK, Kim HJ, Park YH, et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia. 2007; 21(10): 2227-30[DOI][PubMed]
  • 46. Porrata LF, Ristow K, Habermann TM, Witzig TE, Inwards DJ, Markovic SN. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma. Am J Hematol. 2009; 84(2): 93-7[DOI][PubMed]
  • 47. Ho SY, Guo HR, Chen HH, Peng CJ. Nutritional predictors of survival in terminally ill cancer patients. J Formos Med Assoc. 2003; 102(8): 544-50[PubMed]
  • 48. Gibbs J, Cull W, Henderson W, Daley J, Hur K, Khuri SF. Preoperative serum albumin level as a predictor of operative mortality and morbidity: results from the National VA Surgical Risk Study. Arch Surg. 1999; 134(1): 36-42[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments